Brad Webb brings three decades of entrepreneurial and investing experience in the biomedical and biotechnology industries to CCV. Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
Brad led CCV’s investments in Genalyte and co-led CCV’s investment in AssureX and Numedii. He represents CCV on the Boards of all three companies.
Prior to CCV, Brad worked in the medical device industry, mainly focused on devices and procedures used in eye surgery. Brad was a founding member of several start-up ventures in the ophthalmic products industry, mainly responsible for research, clinical and regulatory affairs. Brad was the founder of Vision Biology which developed new viscoelastic products used in eye surgery (acquired by Alcon Laboratories, now a division of Novartis). Previously, Brad was a Research & Development scientist at 3M Company in the ophthalmology products division, where he led product design teams and supervised clinical trials and regulatory processes. He has recently participated in investments in several biotech and medical technology companies.
Brad holds a PhD from the University of California Santa Barbara in Biochemistry and Molecular Biology, and a Masters Degree and Bachelor’s degree in Chemistry. Brad is a member of Tech Coast Angels, is active with UC Santa Barbara technology programs and advises several startups.